Natural killer group 2 member A, Programmed cell death protein 1, and Cytotoxic T-lymphocyte-associated protein 4 (NKG2A + PD-1 / CTLA-4)

The target NKG2A + PD-1 / CTLA-4 refers to a therapeutic strategy or multi-specific approach targeting three distinct inhibitory immune checkpoint receptors: Natural Killer Group 2 Member A (NKG2A), Programmed Cell Death Protein 1 (PD-1), and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) [1, 6, 14]. NKG2A is a C-type lectin-like receptor expressed on Natural Killer (NK) cells and CD8+ T cells that binds to HLA-E to inhibit cytotoxic functions [6, 7]. PD-1 and CTLA-4 are members of the immunoglobulin superfamily that regulate T cell activation at different stages; CTLA-4 primarily acts during the priming phase in lymphoid tissues, while PD-1 modulates the effector phase in peripheral tissues [14, 15]. In many cancers, these pathways are co-opted to create an immunosuppressive microenvironment, often with co-expression of these receptors on exhausted immune cells [8, 9]. Blocking these targets simultaneously aims to synergistically restore both innate and adaptive anti-tumor immunity, potentially overcoming resistance to single-agent checkpoint inhibitors [1, 10]. Clinical trials and preclinical models have explored combinations such as monalizumab (anti-NKG2A) with durvalumab (anti-PD-L1) or ipilimumab (anti-CTLA-4) to enhance therapeutic efficacy in solid tumors [8, 12]. This triple-targeting approach is designed to unleash a broader immune response by activating both the innate and adaptive arms of the immune system [4, 5]. However, the increased potency of such combinations also raises the risk of immune-related adverse events, requiring careful patient selection and monitoring [11, 14].

Other names

KLRC1CD159aPDCD1CD279CD152Killer cell lectin-like receptor subfamily C member 1Programmed cell death protein 1Cytotoxic T-lymphocyte-associated protein 4

Simultaneous blockade of multiple inhibitory immune checkpoints to enhance anti-tumor activity by restoring the function of exhausted T cells and NK cells.